

GENERAL ANNOUNCEMENT::RESULTS BRIEFING 1H 2022

Issuer & Securities

Issuer/ Manager

HYPHENS PHARMA INTERNATIONAL LIMITED

Securities

HYPHENS PHARMA INTL LIMITED - SG1EE4000006 - 1J5

Stapled Security

No

Announcement Details

Announcement Title

General Announcement

Date & Time of Broadcast

17-Aug-2022 12:22:36

Status

New

Announcement Sub Title

RESULTS BRIEFING 1H 2022

Announcement Reference

SG220817OTHRQGRD

Submitted By (Co./ Ind. Name)

Lim See Wah

Designation

Executive Chairman and Chief Executive Officer

Description (Please provide a detailed description of the event in the box below)

Please refer to the attached announcement.

This announcement has been reviewed by the Company's Sponsor, SAC Capital Private Limited (the "Sponsor"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "SGX-ST") and the SGX-ST assumes no responsibility for the contents of this announcement including the correctness of any statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Lee Khai Yinn (Tel: +65 6232 3210) at 1 Robinson Road, #21-00 AIA Tower, Singapore 048542.

Attachments

[Hyphens Results Briefing - H1 22.pdf](#)

Total size = 1968K MB



HYPHENS PHARMA INTERNATIONAL LIMITED

Results Briefing 1H 2022

17 AUG 2022



DISCLAIMER

This presentation has been prepared by Hyphens Pharma International Limited (the "**Company**" and, together with its subsidiaries, the "**Group**").

This content in this presentation is being furnished to you on a confidential basis and solely for your information and neither this presentation nor any part thereof may be (i) used or relied upon by any other party or for any other purpose; (ii) copied, photocopied, duplicated, photographed or otherwise reproduced in any form or by any means; or (iii) redistributed, passed on or otherwise disseminated or quoted, directly or indirectly, to any person either in your organisation or elsewhere. None of the Company, SAC Capital Private Limited (the "**Sponsor**") nor any of their respective affiliates, advisors and representatives makes any representation regarding, or assumes any responsibility or liability whatsoever (in negligence or otherwise) for, the accuracy or completeness of, or any errors or omissions in, any information contained herein nor for any loss howsoever arising from any use of the content in this presentation.

By attending or viewing all or part of this presentation, you:

- i. represent and warrant that you are lawfully able to receive this presentation under the laws of the jurisdiction in which you are located and all other applicable laws;
- ii. agree to be bound by the limitations and restrictions described herein; and
- iii. agree to maintain confidentiality regarding the information disclosed in this presentation and to continue to adhere to all applicable securities and insider trading rules and laws in any jurisdiction at all times.

This presentation does not constitute, or form any part of any offer for sale or subscription of, or solicitation of any offer to buy or subscribe for, any securities in Singapore or any other jurisdiction nor shall it or any part of it form the basis of, or be relied on in connection with, any contract or commitment whatsoever.

The information in this presentation is a summary only and does not purport to contain all of the information that may be required to evaluate the Company or any potential transaction. Any potential transaction could be made available to you in accordance with applicable laws and regulations, including the distribution of any required documents for such potential transaction and such documents will supersede all prior information provided to you, herein or otherwise. Information in this presentation is qualified in its entirety by reference to an offering document for any potential transaction, if it proceeds.

None of the Company, the Sponsor, and any of their respective holding companies, subsidiaries, associated undertakings, controlling persons, affiliates, and any of their respective directors, officers, partners, employees, agents, advisers or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising, whether directly or indirectly, from any use, reliance or distribution of this presentation or its contents or otherwise arising in connection with this presentation. It is not the intention to provide, and you may not rely on the content of this presentation as providing, a complete or comprehensive analysis of the Company's or the Group's financial or trading position or prospects. The information and opinions contained in this presentation is provided as at the date hereof (unless otherwise indicated) and are subject to change without notice. This presentation may not contain all material information concerning the Company or the Group.

The information contained in this presentation has not been independently verified. The accuracy and completeness of the information and opinions in this presentation is not guaranteed and no representation or warranty, expressed or implied, is made as to, and no reliance, in whole or in part, should be placed on the fairness, accuracy, completeness or correctness of the information, opinions or assumptions contained herein. Further, nothing in this presentation should be construed as constituting legal, business, tax or financial advice. None of the Sponsor and its subsidiaries or affiliates has independently verified, approved or endorsed the material herein.

The information in this presentation includes historical information about and relevant to the Group that should not be regarded as an indication of the future performance of the Group or the value of the shares of the Company. This presentation also contains forward-looking statements that may be identified by their use of words like "plans", "expects", "will", "anticipates", "believes", "intends", "depends", "projects", "estimates" or other words of similar meaning and that involve assumptions, risks and uncertainties. All statements that address expectations or projections about the future and all statements other than statements of historical facts included in this presentation, including, but not limited to, statements about the strategy for growth, product development, market position, expenditures, and financial results, are forward-looking statements. Such forward-looking statements are based on certain assumptions and expectations of future events regarding the Group's present and future business strategies and the environment in which the Group will operate, and must be read together with those assumptions. No assurance or guarantee is given that these assumptions and expectations are accurate or will be realised. Actual future performance, outcomes and results may differ materially from those expressed in forward-looking statements as a result of a number of risks, uncertainties and assumptions. These risks, uncertainties and assumptions include, without limitation, general industry and economic conditions, interest rate trends, cost of capital and capital availability, competition from other entities, shifts in customer demand, customers and partners, changes in operating expenses including employee wages, benefits and training, governmental and public policy changes and the continued availability of financing in the amounts and the terms necessary to support future business. Predictions, projections or forecasts of the economy or economic trends of the markets are not necessarily indicative of the future or likely performance of the Group. Past performance is not necessarily indicative of future performance. You are cautioned not to place undue reliance on these forward-looking statements, which are based on the Company's current view of future events. None of the Company and the Sponsor, their respective affiliates and their respective agents assumes any responsibility to amend, modify or revise any forward-looking statements, on the basis of any subsequent developments, information or events, or otherwise.

Neither this presentation nor any of its content may be used without the prior written consent of the Company and the Sponsor. Any forwarding, distribution or reproduction of the information in this presentation electronically or otherwise, in whole or in part, is unauthorised.




FINANCIAL RESULTS






1.1 FINANCIAL PERFORMANCE

Revenue (S\$'m)



Profit After Tax (S\$'m)




* Excl JSS






1.2 FINANCIAL PERFORMANCE (WITHOUT NOVEM)

Revenue (S\$'m)



Profit After Tax (S\$'m)




† Excludes Novem Revenue and Profit (acquired in Dec 2021)

* Excl JSS



1.3 EBITDA OVER THE YEARS



* Exclude goodwill impairment



1.4 INCOME STATEMENT

	1H2022	1H2021	YoY
	S\$000	S\$000	%
Revenue	80,704	63,807	26.5%
Cost of sales	(49,627)	(39,055)	27.1%
Gross profit	31,077	24,752	25.6%
Other income and gains	343	348	-1.4%
Distribution costs	(16,874)	(14,271)	18.2%
Administrative expenses	(6,197)	(5,234)	18.4%
Finance costs	(66)	(48)	37.5%
Other losses	(683)	(317)	115.5%
Share of profit of associate	230	-	N.M.
Profit before tax	7,830	5,230	49.7%
Income tax expense	(1,589)	(915)	73.7%
Profit after tax	6,241	4,315	44.6%

N.M.: not meaningful


1H2022 vs 1H2021

- Revenue increased across all business segments and most geographical locations. Novem contributed \$9.2mil in revenue; Hyphens organic growth at 12%.
- GPM remained comparable at 38.5% (1H2021: 38.8%)
- Increase in distribution costs in tandem with increased revenue.
- Increase in admin exp due to higher cost base with inclusion of Novem.
- Exceptional profit achieved in 1H2022 (+44.6% against 1H2021)




1.5

REVENUE BY BUSINESS SEGMENTS





EBITDA MARGIN BY BUSINESS SEGMENTS



Notes:

Due to restatement of revenue in prior years to be consistent with FY2021, prior years' EBITDA margins have been updated accordingly.



2

FINANCIAL POSITION

S\$'000	30 Jun 2022	31 Dec 2021
Total assets	104,459	99,191
Inventories	20,700	25,290
Trade & other receivables	30,565	28,722
Cash & cash equivalents	28,444	19,461
Total liabilities	39,452	44,455
Trade & other payables	30,678	33,563
Bank borrowings	3,661	6,075
Total equity	65,007	54,736
Equity attributable to shareholders	63,742	54,736
NAV per share (cents)	20.64	17.73





CASHFLOW STATEMENT

S\$'000	1H2022	1H2021
<u>Cashflow from operating activities</u>		
Profit before tax	7,830	5,230
Adjustments for non-cash/non-op items	1,267	1,056
Changes in working capital	(50)	1,003
Tax paid	(842)	(1,023)
Cashflow from operating activities	8,205	6,266
Cashflow used in investing activities	(165)	(138)
Cashflow from/(used in) financing activities	943	(2,733)
Net cash inflow	8,983	3,395
Cash & cash equiv, beg balance	19,461	27,526
Cash & cash equiv, ending balance	28,444	30,921



KEY CONTRIBUTIONS TO THE PERFORMANCE

1. Post-COVID recover:

- Our major market of Singapore, Malaysia and Vietnam registered positive and double digit improvement in sales performance.

2. Additional of Novem to the Group.

- Contributed positively to both top and bottom line.



BUSINESS UPDATES




Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group



SUCCESSFULLY RAISED S\$6M FOR OUR SUBSIDIARY DOCMED

VALUING DOCMED AT S\$60M



Hyphens Pharma International

Price target:
PhillipCapital 'buy' 43 cents



Investment from Metro

PhillipCapital Research analyst Paul Chew has upgraded Hyphens Pharma from "accumulate" to "buy" as he sees digital healthcare being a new growth and stock catalyst.

"Hyphens Pharma's underlying growth strategy is to be a leading portfolio of proprietary skin health products and brands across Asia," says Chew, who has also updated his target price to 43 cents from 34.5 cents.

In addition, Chew has raised FY2022 ending December earnings by 40% to \$9.2 million to incorporate earnings from the acquisition of Novem.

On May 27, Hyphens Pharma announced that Metro Holdings, a property and retail company, will be investing \$6 million for a 10% stake in DocMed Technology (DocMed), valuing it at \$60 million.

A digital health platform, DocMed is a subsidiary of Hyphens Pharma.

DocMed owns Hyphens Pharma's medical B2B hypermart POM Medical Hypermart (POM) and a licensed e-pharmacy Wellway POM's revenue in FY2021 came in at \$41 million including offline sales.

DocMed will use the proceeds to build up its manpower across technology, operations and marketing areas and enhance its B2B platform to serve doctors. The platform can be enhanced with more pharmaceutical offerings, mobile features and a regional footprint across Asean. The expected timeline to enhance and expand the B2B platform is two years.

Chew views the transaction as a funding event rather than crystallisation or monetisation of Hyphens digital assets.

"The proceeds have the potential to enhance the B2B platform with more doctors, pharmaceutical companies, transactions and new sources of revenue," the analyst writes. "Such milestones could drive further rounds of financing and higher valuations."

The analyst also notes that DocMed's platform will be an important space to showcase drugs to doctors. In turn, DocMed can generate new sources of revenue such as advertising and promotion from pharmaceutical companies.

Overall, Chew sees the creation and development of the digital healthcare platform DocMed as an additional growth and share price catalyst for Hyphens Pharma, with near-term earnings drivers being the acquisition of Novem and growth in specialty pharma sales due to the return of elective surgeries post-Covid-19. This is considering Hyphens Pharma's multiple-year growth strategy to expand its proprietary brands of skincare products across the region. — Chloe Lim



Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group




SUCCESSFUL REGISTRATION & LAUNCH OF OCEAN HEALTH PRODUCTS OUTSIDE OF SINGAPORE



Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group





People, Organisation & Culture

Project Symphony

“

Clearly stipulate vision/core values that genuinely represent our current behaviour and aspirations.

The process will gel and energize us as a team to enable us to become winners in the market competition.

”



Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group




LICENSED LEDERLON®

An ***Exclusive License & Supply agreement*** for 10 years from date of signature with auto-renewal.

An intra-articular corticosteroid that is different from currently registered product, for the treatment of osteoarthritis.

Licensed from Esteve Group, a mid size European specialty pharmaceutical company.



CESSATION OF DISTRIBUTORSHIP WITH BIOSENSORS INTERVENTIONAL

- Agreement will lapse by end of 2022.
- Agreement ended amicably.
- Contributed to 3% of revenue in FY 21.
 - Contributed to 6% of revenue in 1H 22.
 - Contributed to 12% of revenue in FY 17.

BUSINESS OUTLOOK



Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group



INVESTING FOR GROWTH

1. Investment in Proprietary Brands

2. Internationalisation

3. Going Digital

Docmed is expected to speed up hiring and deployment of the fund raised.

4. Strengthen Specialty Pharma Portfolio

5. Acquisitions



QUESTIONS & ANSWERS





Hyphens Pharma International Limited (SGX: 1J5)
16 Tai Seng Street, Level 4, Singapore 534138
www.hyphensgroup.com

in | Follow us on LinkedIn